Therefore, targeting of PTK6 may serve as a therapeutic strategy for metastatic breast cancer and other cancer types.At the same time, many compounds have also been proved to inhibit the tumor process by inhibiting the expression of PTK6, such as (E)-5-(benzylideneamino)-1 h-Benzo [d]imidazol-2(3H), semi-synthetically optimized sipholenol A ester, and 4-aniline-substituted α-carboline compounds [17–19]. Here, PTK6 is linked to neoplasm.